Back to results
US 2026/0102420 A1Published application
Cancer immunotherapy
AssigneeHoffmann-La Roche Inc.
InventorsStephan Gasser, Katrin Groebke Zbinden, Claudio Murgia, Tobias Schmidt, Antonio Sorrentino, Pablo Umaña
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies employing T cell activation and UAP1 inhibitors, and the use of these combination therapies for the treatment of cancer.
Claims47
(canceled)
A method for treatment of cancer in an individual,
- wherein said method comprises:
- (a) administration of a therapeutically effective dose of UDP-N-acetylhexosamine pyrophosphorylase (UAP1) inhibitor to the individual, and
- (b) administration of a therapeutically effective dose of an immunotherapy to the individual.
(canceled)
(canceled)
9-12. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
44-46. (canceled)
(canceled)
Dependencies are inferred from the claim text.